Drug intelligence / Profile preview

clidaborol

Development stage: Preclinical
Modality: Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Topical

Overview

Clidaborol is a boron-containing compound that has been investigated as a topical anti-inflammatory and antimicrobial agent, particularly for dermatological use. It is structurally related to other boron-based drugs but is distinct from them. Clidaborol's mechanism of action involves inhibition of inflammatory pathways and possible antibacterial activity, making it a candidate for the treatment of skin conditions such as atopic dermatitis and psoriasis. However, there is limited publicly available clinical or regulatory information on its current development status or approval.

Beyond the preview

Go deeper on clidaborol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clidaborol.

Explore the full profile